Legal Representation
Attorney
Thomas A. Polcyn
USPTO Deadlines
Next Deadline
7 days remaining
Examiner's Amendment Completed
Due Date
July 26, 2025
Application History
18 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jul 15, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 11, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Jul 11, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Jul 11, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Jul 11, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Jul 3, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jul 3, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jul 3, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
May 24, 2025 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
May 5, 2025 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
May 5, 2025 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Mar 20, 2025 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Mar 19, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Mar 17, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jan 3, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Nov 4, 2024 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Nov 4, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Oct 31, 2024 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and medical preparations for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; chemical preparations for medical and pharmaceutical purposes, namely, for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; pharmaceutical and medical preparations for use in relation to treating fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs, namely, medicinal preparations for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; antibodies; pharmaceutical and medical preparations incorporating antibodies for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair
Class 042
Scientific research and development services; Scientific research in the nature of conducting clinical trials for others; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and product design of pharmaceutical and medical preparations; pharmaceutical drug development and discovery services; laboratory and medical laboratory product research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaid
Classification
International Classes
005
042